JUNS - Jupiter Neurosciences Inc Analyst Consensus Forecast
Jupiter Neurosciences Inc (JUNS) is establishing itself as a promising player in the eyes of physicians, creating a foundation for combating brain pathologies. Management possesses deep expertise in neurotherapy, ensuring transparency in early-stage research. This price chart reflects a valuation level of 1880.11. The business relies on a unique method of transporting drugs across the blood-brain barrier, guaranteeing global reach with minimal costs.
Analytical breakdowns for Jupiter Neurosciences (JUNS)
- stock quotes and analyst forecast:
- market capitalization statistics:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio Jupiter Neurosciences Inc|JUNS - Long-Term Debt to Capital|Current Liabilities to Capital Jupiter Neurosciences, Inc.|JUNS - Company Total Debt|Debts to Book Capitalization Jupiter Neurosciences|JUNS - Company Long-Term Debt|Company Short-Term Loans and Borrowings Jupiter Neurosciences|Immediate Liquidity jupiterneurosciences.com
- net income and valuation multiples indicators:
JUNS - Company Net Income|Future Net Profit Jupiter Neurosciences Inc|JUNS - Price to Earnings Ratio|Forward P/E Multiple jupiterneurosciences.com|JUNS - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Jupiter Neurosciences|JUNS - Operating profit EBITDA|Net earnings per share for the last four quarters Jupiter Neurosciences|JUNS - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months jupiterneurosciences.com|JUNS - Earnings growth in current year|Expected net earnings per share growth next year Jupiter Neurosciences Inc
Summary company analytics:JUNS jupiterneurosciences.com
This indicator measures the weighted average expectation of the professional community regarding the asset's fair value, determining the potential for capitalization growth by aggregating the target prices of various analysts. The trend of the consolidated target forecast from investment houses reflects market confidence in the success of drug development, where valuation stability confirms the effectiveness of investments in the high-paid staff of leading neurobiologists and the advanced research base of Jupiter Neurosciences Inc (JUNS).
Competitors of Jupiter Neurosciences Inc
Analyst Forecast Prices BIIB|Neurocrine Biosciences, Inc. - Consensus Target|Analyst Consensus Forecast Regencell Bioscience Ltd RGC|AXSM - Price Target Chart|ACAD (ACADIA Corp) - Broker Consensus Forecast|Xenon Pharmaceuticals (XENE) - Price Target Chart|VKTX - Analyst Median Target|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|Price Target Chart Prothena Corporation PLC|ALEC (Alector Therapeutics) - Analyst Forecast Prices|Consensus Target ANNX (Annexon)|Analyst Consensus Forecast omeros.com (OMER)|Price Target Chart Neurogene Corp NGNE|ACIU (AC Immune Inc) - Forecast Levels Chart|Voyager Therapeutics - Analyst Consensus Forecast|Analyst Median Target neumoratx.com NMRA|SCLX (Scilex) - Consensus Target|TVGN: Analyst Forecast Prices|ACOG (Alpha Cognition Inc) - Analyst Consensus Forecast|Average Forecast Price cogrx.com CGTX|Price Target Chart Inhibikase Therapeutics (IKT)|SAVA (cassavasciences.com) - Fair Value Consensus|Assertio - Consensus Target|Fair Value Consensus COYA|VTGN - Price Target Chart|OVID (Ovid Therapeutics Inc.) - Broker Consensus Forecast|ABOS: Analyst Consensus Forecast|Average Forecast Price cervomed.com (CRVO)|Consensus Target ATHE|Analyst Consensus Forecast Clene Nanomedicine|Price Target Chart PepGen Inc. (PEPG)|RLMD (Relmada Corp) - Fair Value Consensus|Price Target Chart Annovis Bio, Inc. ANVS|Grace Therapeutics Inc (GRCE) - Average Forecast Price|AIFF - Price Target Chart|Analyst Median Target Klotho Neurosciences Inc KLTO|NRSN: Analyst Consensus Forecast|Consensus Target Reviva Pharmaceuticals, Inc.|MTVA (MetaVia Inc.) - Analyst Consensus Forecast|neuraxis.com (NRXS) - Analyst Median Target|Analyst Consensus Forecast HSDT|PASG - Average Forecast Price|Price Target Chart Neuphoria Therapeutics NEUP|NERV: Broker Consensus Forecast|Athira Pharma, Inc. - Analyst Consensus Forecast|addextherapeutics.com (ADXN) - Consensus Target|ALZN: Analyst Consensus Forecast|Average Forecast Price Cyclerion Therapeutics, Inc. (CYCN)|Price Target Chart Protagenic Therapeutics Inc.|Pasithea (KTTA) - Analyst Median Target|Consensus Target CRGT (Cortigent, Inc.)|ATXI (avenuetx.com) - Fair Value Consensus|Analyst Consensus Forecast BCLI (BrainStorm Cell Therapeutics)|Analyst Median Target Cara Therapeutics Inc. (CARA)|CHRO - Price Target Chart|ELYM (Eliem Therapeutics) - Broker Consensus Forecast|ITCI: Analyst Consensus Forecast|Consensus Target longboardpharma.com|Price Target Chart Marinus Pharmaceuticals, Inc.|NKGN (NKGen Biotech Inc) - Analyst Forecast Prices|Consensus Target NRBO (NeuroBo)|Analyst Consensus Forecast Sage Therapeutics Inc (SAGE)|Price Target Chart Synaptogenix, Inc. SNPX|TRVN: Broker Consensus Forecast|VIGL - Price Target Chart|Analyst Median Target Anew Medical Inc. WENA|Cerevel (CERE) - Price Target Chart
